🎙️ JLS Podcast: William Leonard Pickard interviews Bryan Hubbard, Executive Director of the American Ibogaine Initiative 🚀 Background on Bryan Hubbard: Legal expert, policy leader, and addiction recovery advocate with deep roots in underserved communities. Formerly: Chairman of the Kentucky Opioid Abatement Advisory Commission Special Counsel, KY Attorney General’s Office of Medicaid Fraud Commissioner, KY Department of Income Support Currently: Executive Director, American Ibogaine Initiative (via the REID Foundation) CEO, Americans for Ibogaine, a nonprofit advancing awareness and research around ibogaine's neurorestorative potential. 🧠 From Policy to Psychedelic Advocacy Hubbard’s work is fueled by a commitment to ending cycles of addiction, poverty, and systemic neglect. Became a national voice in the movement to integrate ibogaine into mainstream treatment options for opioid use disorder and traumatic brain injury. 💸 The Texas Ibogaine Initiative In partnership with former Texas Governor Rick Perry, Bryan helped secure $50 million in state funding for ibogaine research and drug development. This state-backed initiative marks one of the most significant public investments in psychedelic medicine to date — aiming to bring ibogaine through FDA trials and into legal clinical use. 🌿 What Is Ibogaine? Ibogaine is a naturally occurring psychoactive compound known for its powerful addiction-interrupting effects and potential to heal the brain. Current research points to: Disruption of opioid dependency pathways Neurorestoration after prolonged substance abuse Possible applications in PTSD, depression, and traumatic brain injury ⚖️ A New Frontier in Drug Policy Hubbard speaks on the legal and political challenges of integrating psychedelics into public health frameworks. He emphasizes: The need for state and federal collaboration Bridging science, policy, and public trust Centering underserved communities in treatment access 🔍 What’s Next American Ibogaine Initiative is preparing for clinical trials backed by state funding. Public-private partnerships are key to unlocking large-scale access. Growing bipartisan interest in psychedelics signals a major shift in U.S. drug policy. 🏆 Final Takeaways Bryan Hubbard is one of the most strategic and passionate voices working to medicalize ibogaine and transform addiction treatment in America. His blend of legal acumen, policy leadership, and heartfelt advocacy puts him at the center of a new era in mental health reform. ✨ Support this work and unlock exclusive interviews with Bryan Hubbard, biotech CEOs, ethicists, and pioneers in AI drug design on Patreon:  https://www.patreon.com/c/thelastalchemist 🔗 Stay tuned for more updates from the frontlines of psychedelic medicine, policy, and healing.